Mundipharma names Marc Princen as Global Chief Executive Officer
Marc Princen was revealed in mid-June as the new Global Chief Executive Officer (CEO) of the Mundipharma network, having taken up the role officially on 1 June.
In his new position, Princen will have global oversight of all Mundipharma’s strategic and operational functions, and will also shoulder responsibility for delivery of the company’s 2020-2024 Business Plan.
Boasting a career over three decades long in the pharmaceutical industry with commercial, marketing, and business development experience, Princen jumped ship to Mundipharma from Allergan, where he most recently held the role of Executive Vice President and President, International Business.
Princen was previously Takeda’s President, Europe and Canada, and he has spent more than 15 years at Schering-Plough, which later became MSD.
“Marc is a highly proven pharmaceutical executive with a strong track record at leading pharma companies such as Schering-Plough, MSD, Takeda and Allergan,” commented Mundipharma Chairman Jacques Theurillat. “He is widely recognised for his expertise in business change and transformation and joins us at an important moment as we continue our evolution as an organisation. I wish him every success in his role with us.”
Princen himself said he was “proud and delighted” to be joining the firm “at this pivotal time. I see a genuine opportunity to help build a new and exciting future for the organisation as it continues on its transformation journey.”
European Commission has moved to expand the existing approved indication for Mundipharma’s Invokana (canagliflozin), making …
UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, …